Literature DB >> 22661277

Assessment of endothelial function in patients with nonalcoholic fatty liver disease.

Yasar Colak1, Ebubekir Senates, Atakan Yesil, Yusuf Yilmaz, Oguzhan Ozturk, Levent Doganay, Ender Coskunpinar, Ozlem Timirci Kahraman, Banu Mesci, Celal Ulasoglu, Ilyas Tuncer.   

Abstract

In this study, we aimed to evaluate the endothelial functions in patients with nonalcoholic fatty liver disease (NAFLD). In this observational case-control study, a total of 51 patients with NAFLD in study group and a total of 21 with age- and sex-equivalent individuals in control group were enrolled. In both patients and control groups, levels of asymmetric dimethylarginine (ADMA), systemic endothelial function (brachial artery flow-mediated dilation) (FMD) and carotid artery intima-media thickness (C-IMT) were measured. FMD and C-IMT were evaluated by vascular ultrasound. Plasma levels of ADMA were measured by ELISA. C-IMT was significantly higher in patients with NAFLD group than control group (0.67 ± 0.09 vs. 0.52 ± 0.11 mm, P < 0.001). The average C-IMT measurements were found in groups of control, simple steatosis, and NAFLD with (borderline and definite) NASH as 0.52 ± 0.11, 0.63 ± 0.07, and 0.68 ± 0.1 mm, respectively. The differences between groups were significant (P < 0.001). Measurement of brachial artery FMD was significantly lower in patients with NAFLD group compared to control group (7.3 ± 4.8 vs. 12.5 ± 7.1 %, P < 0.001). FMD measurements in groups of control, the simple steatosis, and NAFLD with NASH as 12.5 ± 7.1, 9.64 ± 6.63, and 7.03 ± 4.57 %, respectively, and the differences were statistically significant (P < 0.001). The increase in C-IMT and decrease in FMD was independent from metabolic syndrome and it was also more evident in patients with simple steatosis and NASH compared to control group. There was no significant difference between the control and NAFLD groups in terms of plasma ADMA levels (0.61 ± 0.11 vs. 0.69 ± 0.37 μmol/L, P = 0.209). Our data suggested that NAFLD is associated with endothelial dysfunction and increased earlier in patients with atherosclerosis compared to control subjects.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22661277     DOI: 10.1007/s12020-012-9712-1

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  39 in total

1.  Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease.

Authors:  Takhar Kasumov; John M Edmison; Srinivasan Dasarathy; Carole Bennett; Rocio Lopez; Satish C Kalhan
Journal:  Metabolism       Date:  2010-09-23       Impact factor: 8.694

Review 2.  Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

Authors:  Giovanni Targher; Christopher P Day; Enzo Bonora
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

3.  Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study.

Authors:  Leon A Adams; Scott Harmsen; Jennifer L St Sauver; Phunchai Charatcharoenwitthaya; Felicity B Enders; Terry Therneau; Paul Angulo
Journal:  Am J Gastroenterol       Date:  2010-02-09       Impact factor: 10.864

4.  Endothelial dysfunction and non-alcoholic liver steatosis in hypertensive patients.

Authors:  A Sciacqua; M Perticone; S Miceli; I Laino; E J Tassone; R D Grembiale; F Andreozzi; G Sesti; F Perticone
Journal:  Nutr Metab Cardiovasc Dis       Date:  2010-03-12       Impact factor: 4.222

5.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

Review 6.  Endothelial dysfunction: a marker of atherosclerotic risk.

Authors:  Piero O Bonetti; Lilach O Lerman; Amir Lerman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-02-01       Impact factor: 8.311

Review 7.  Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.

Authors:  Kenneth Cusi
Journal:  Gastroenterology       Date:  2012-02-08       Impact factor: 22.682

8.  Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2.

Authors:  John Willy Haukeland; Jan Kristian Damås; Zbigniew Konopski; Else Marit Løberg; Terese Haaland; Ingeborg Goverud; Peter A Torjesen; Kåre Birkeland; Kristian Bjøro; Pål Aukrust
Journal:  J Hepatol       Date:  2006-03-20       Impact factor: 25.083

9.  Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis.

Authors:  D S Celermajer; K E Sorensen; V M Gooch; D J Spiegelhalter; O I Miller; I D Sullivan; J K Lloyd; J E Deanfield
Journal:  Lancet       Date:  1992-11-07       Impact factor: 79.321

10.  Endothelial dysfunction in Turkish patients with non-alcoholic fatty liver disease.

Authors:  O Senturk; O Kocaman; S Hulagu; T Sahin; C Aygun; T Konduk; A Celebi
Journal:  Intern Med J       Date:  2007-08-28       Impact factor: 2.048

View more
  31 in total

1.  MCD diet-induced steatohepatitis is associated with alterations in asymmetric dimethylarginine (ADMA) and its transporters.

Authors:  Laura G Di Pasqua; Clarissa Berardo; Vittoria Rizzo; Plinio Richelmi; Anna Cleta Croce; Mariapia Vairetti; Andrea Ferrigno
Journal:  Mol Cell Biochem       Date:  2016-06-29       Impact factor: 3.396

2.  Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease.

Authors:  Oguzhan Ozturk; Yasar Colak; Ebubekir Senates; Yusuf Yilmaz; Celal Ulasoglu; Levent Doganay; Seyma Ozkanli; Yasemin Musteri Oltulu; Ender Coskunpinar; Ilyas Tuncer
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

Review 3.  Nonalcoholic fatty liver disease and cardiovascular disease.

Authors:  Hong Liu; Hong-Yun Lu
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

4.  Nonalcoholic fatty liver disease and vascular function: cross-sectional analysis in the Framingham heart study.

Authors:  Michelle T Long; Na Wang; Martin G Larson; Gary F Mitchell; Joseph Palmisano; Ramachandran S Vasan; Udo Hoffmann; Elizabeth K Speliotes; Joseph A Vita; Emelia J Benjamin; Caroline S Fox; Naomi M Hamburg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-03-05       Impact factor: 8.311

Review 5.  Nonalcoholic fatty liver disease: implications for cardiovascular risk.

Authors:  Amreen Dinani; Arun Sanyal
Journal:  Cardiovasc Endocrinol       Date:  2017-05-17

Review 6.  The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease.

Authors:  Sven M Francque
Journal:  Eur Cardiol       Date:  2014-07

Review 7.  Non-alcoholic fatty liver disease: a diabetologist's perspective.

Authors:  Joseph M Pappachan; Farrah A Antonio; Mahamood Edavalath; Arjun Mukherjee
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

Review 8.  Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease.

Authors:  Stefano Ballestri; Amedeo Lonardo; Stefano Bonapace; Christopher D Byrne; Paola Loria; Giovanni Targher
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 9.  Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis.

Authors:  Licia Polimeni; Maria Del Ben; Francesco Baratta; Ludovica Perri; Fabiana Albanese; Daniele Pastori; Francesco Violi; Francesco Angelico
Journal:  World J Hepatol       Date:  2015-06-08

Review 10.  Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.

Authors:  Quentin M Anstee; Giovanni Targher; Christopher P Day
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-19       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.